How Is Fatty Liver Treated? Diet, Drugs, and More

Fatty liver disease is treated primarily through lifestyle changes, especially weight loss, dietary shifts, and exercise, with a growing number of medications now entering the picture for more advanced cases. For most people, losing around 5 to 10 percent of body weight can dramatically reduce liver fat and even reverse inflammation and scarring. In 2024, the first drug specifically approved for the inflammatory form of the disease reached the market, marking a turning point after decades of having no targeted pharmaceutical option. The treatment landscape is broader and more nuanced than it was even a few years ago, and the right approach depends heavily on how far the disease has progressed.

A Quick Note on the Name Change

If you’ve been reading about this condition, you may have encountered two sets of terminology. What doctors used to call nonalcoholic fatty liver disease (NAFLD) is now officially known as metabolic dysfunction-associated steatotic liver disease, or MASLD. The inflammatory subtype, previously called NASH, is now MASH. A global consensus adopted the new names to better reflect the metabolic roots of the condition and to remove the word “alcoholic,” which many patients and clinicians felt was stigmatizing.¹ Both naming systems still appear in research and clinical materials, so you’ll see them used interchangeably. In this article, the older terms appear when referencing studies that used them.

Why Progression Matters for Treatment Decisions

Not everyone with fatty liver needs the same intensity of treatment. Simple fat accumulation in the liver without significant inflammation, which is the most common form, progresses slowly. A meta-analysis of paired biopsy studies found that the average person with simple steatosis advanced about one fibrosis stage every 14 years, while those who already had the inflammatory form (NASH/MASH) progressed roughly twice as fast, averaging one stage every seven years.² About a third of patients in that analysis actually saw their fibrosis improve over time, which is encouraging.

The stakes go up sharply when fibrosis reaches advanced stages. Advanced scarring (stages F3 and F4) is the strongest predictor of dying from liver disease or cardiovascular complications.³ Having diabetes or a higher body mass index also independently pushes fibrosis forward faster.⁴ So treatment urgency varies: someone with mild steatosis and no metabolic complications might focus on gradual lifestyle improvement, while someone with moderate fibrosis and diabetes needs a more aggressive, potentially drug-assisted approach.

Weight Loss Is the Single Most Effective Intervention

If there’s one number to remember, it’s this: losing at least 10 percent of your body weight produces dramatic results. In a large prospective study, every single patient who hit that threshold saw improvement on liver biopsy scoring. Among them, 90 percent had complete resolution of NASH, and 45 percent showed regression of fibrosis, meaning actual reversal of scarring.⁵ Even more modest weight loss helps. Roughly 58 percent of people who lost at least 5 percent of their body weight achieved NASH resolution in the same study.

The challenge, of course, is that sustained weight loss is difficult. Clinical trials report these numbers after structured lifestyle programs with close follow-up; real-world adherence is lower. But the dose-response relationship is clear: more weight loss means more liver improvement. This is the treatment that works best, and every other intervention is either a way to support it or a supplement when it falls short.

What to Eat and What to Avoid

The Mediterranean diet has the strongest evidence of any specific dietary pattern for fatty liver. A crossover trial found that six weeks of a traditional Mediterranean diet reduced liver fat by about 39 percent, compared to just 7 percent on a low-fat, high-carbohydrate diet.⁶ The Mediterranean pattern emphasizes olive oil, nuts, fish, vegetables, legumes, and whole grains, while minimizing red meat, refined sugars, and processed foods. It is not a calorie-counting regime so much as a shift in what your calories are made of.

The practical emphasis for fatty liver specifically tends to center on a few points. Fructose, especially from sugar-sweetened beverages, is particularly harmful to the liver because it drives fat production directly in liver cells. Saturated fat from processed and fast food also contributes more to liver fat than unsaturated fat does. On the flip side, omega-3 fatty acids from fish appear protective, and coffee drinking has been consistently associated with lower risk of fibrosis progression in observational studies, though the mechanism is not fully understood. The overall pattern matters more than any single food: shifting toward a whole-food, plant-rich diet with healthy fats and away from sugar and ultra-processed food is the dietary intervention with the most support behind it.

Exercise Works Even Without Weight Loss

One of the more useful findings in fatty liver research is that exercise reduces liver fat independently of weight loss. Both aerobic exercise (walking, cycling, swimming) and resistance training (weight lifting) have been shown to lower liver fat content, improve liver enzyme levels, and reduce insulin resistance.⁷ In one study, resistance training produced about a 13 percent relative reduction in liver fat with no change in body weight, body fat mass, or visceral fat volume.⁸

This is good news for people who struggle with the scale. Even if the number on the scale doesn’t budge, regular physical activity is still improving the liver. Multiple clinical trials confirm that both forms of exercise reduce liver fat.⁹ Most guidelines suggest at least 150 minutes per week of moderate-intensity activity, but the evidence does not clearly favor one type of exercise over another. Pick what you’ll actually stick with.

Resmetirom, the First Approved Drug for MASH

For decades, there was no FDA-approved medication specifically targeting fatty liver disease. That changed in 2024 with resmetirom (brand name Rezdiffra), a thyroid hormone receptor-beta agonist that works selectively in the liver. It essentially mimics the fat-clearing effects of thyroid hormone in liver tissue without causing the systemic effects of actual hyperthyroidism. The pivotal trial showed that resmetirom resolved MASH without worsening fibrosis, with a favorable safety profile.¹⁰

Resmetirom is approved for adults with non-cirrhotic MASH who have moderate to advanced fibrosis, specifically stages F2 and F3.¹¹ It is not a treatment for everyone with a fatty liver. If you have early-stage steatosis without significant fibrosis, lifestyle changes remain the standard recommendation. And if you already have cirrhosis (stage F4), resmetirom has not been studied for your situation. The drug fills an important gap for the patients stuck in the middle: too advanced for lifestyle changes alone to be sufficient, but not yet at the point of needing a transplant discussion.

GLP-1 Receptor Agonists and Related Drugs

The diabetes and obesity drugs that have transformed weight management, including semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound), are showing striking results for fatty liver as well, even though they are not yet specifically approved for it. A systematic review and meta-analysis found that GLP-1 receptor agonists over a median of about six months significantly reduced liver fat content and improved the histological appearance of steatosis, inflammation, and ballooning on biopsy. The evidence for tirzepatide was more robust than for semaglutide or liraglutide individually.¹²

One important caveat: while these drugs improve steatosis and inflammation, they have not yet convincingly improved fibrosis, which is the outcome most tied to mortality. Animal studies of tirzepatide suggest it combats fat accumulation, inflammation, and fibrosis markers in the liver,¹³ but the human data on fibrosis improvement from GLP-1 drugs remains underwhelming so far. That may change as longer trials report results. For now, many clinicians prescribe these medications off-label for patients who have both metabolic disease and fatty liver, because the weight loss and metabolic improvements they drive do indirectly benefit the liver.

Other Medications Used Off-Label

Several other drug classes show up in treatment discussions, though none have specific fatty liver approval:

Pioglitazone: This older diabetes drug reduces liver fat substantially. One trial found it lowered liver fat by about 7.5 percentage points (measured by MRI) and significantly improved liver stiffness over 24 weeks.¹⁴ The trade-off is weight gain and fluid retention, which makes it a tough sell for many patients.
SGLT2 inhibitors: Drugs like empagliflozin and dapagliflozin, widely used for type 2 diabetes and heart failure, were found in a meta-analysis to be more effective than pioglitazone at reducing fibrosis scores, visceral fat, and BMI in Asian patients with both fatty liver and diabetes.¹⁵ They also promote modest weight loss, which gives them an advantage over pioglitazone for patients worried about their weight.
Vitamin E: A Cochrane review found that the evidence for vitamin E in fatty liver is very low certainty, with slight reductions in liver enzymes but unknown impact on the clinical course of the disease.¹⁶ However, a more recent randomized controlled trial found that 300 mg daily of vitamin E produced histological improvements in steatosis, inflammation, and even fibrosis, with about 29 percent of the vitamin E group achieving the primary biopsy endpoint versus 14 percent on placebo.¹⁷ The mixed signals mean vitamin E is still debated. It is sometimes recommended for patients with biopsy-confirmed MASH who do not have diabetes, but long-term safety concerns (including a possible increased risk of prostate cancer at high doses, from older studies) limit enthusiasm.

When Surgery Becomes an Option

Bariatric surgery is the most effective intervention for severe fatty liver in people with obesity, though it’s obviously a much bigger step than adjusting your diet. The results at five years are remarkable: NASH resolved in 84 percent of patients, and fibrosis decreased in about 70 percent, with more than half of all patients seeing their fibrosis disappear entirely. Fibrosis continued to improve between the one-year and five-year mark, suggesting the liver keeps healing long after the initial weight loss.¹⁸

There is a catch. Even with the dramatic weight loss that bariatric surgery produces, nearly half of patients with advanced fibrosis still had some persistent scarring on follow-up biopsy, particularly those who lost less weight or who didn’t achieve remission of diabetes or hypertension.¹⁹ Surgery is powerful, but it is not a guaranteed cure for fibrosis once it is well established. It tends to be reserved for people with a BMI above 35 (or above 30 with significant metabolic complications) who have not succeeded with lifestyle changes alone.

Alcohol and Fatty Liver Are a Worse Combination Than Many Realize

There’s a persistent misconception that “nonalcoholic” fatty liver disease means alcohol doesn’t matter. It does. Even low-to-moderate drinking is independently associated with more fibrosis and a higher likelihood of having at-risk MASH in people who already have the metabolic form of the disease. A study found a dose-dependent increase in significant fibrosis and at-risk MASH as weekly drinks increased, with a validation cohort confirming about 70 percent higher odds of disease progression in moderate drinkers.²⁰

The relationship also differs between men and women. In men with metabolic fatty liver, all-cause mortality rose in a straight-line relationship with weekly alcohol intake. In women, mortality stayed relatively flat up to about two drinks per week and then climbed steeply, with a sharper increase than in men.²¹ The practical takeaway is that if you have fatty liver disease, even modest drinking is working against your liver’s recovery.

How Doctors Track Whether Treatment Is Working

Liver biopsy remains the gold standard for diagnosing and staging fatty liver disease, but it is invasive, painful, and not something you want to repeat every six months. MRI-based techniques are increasingly used instead. MRI-PDFF (proton density fat fraction) provides a precise, quantitative measure of liver fat content that is emerging as a reliable endpoint in clinical trials.²² A 30 percent relative drop in MRI-PDFF independently predicted fibrosis regression on subsequent biopsy, with over six times the odds of improvement compared to patients without that level of fat reduction.²³

In everyday clinical practice, not everyone gets an MRI. Ultrasound-based tools like controlled attenuation parameter (CAP), available on the same FibroScan devices used to measure liver stiffness, offer a cheaper and more accessible way to estimate fat content, though with less precision than MRI.²⁴ Blood tests like the FIB-4 index (a simple formula using age, liver enzymes, and platelet count) are widely used as an initial screen to estimate fibrosis risk, with more advanced imaging reserved for borderline or high-risk results. Knowing where you stand on fibrosis stage is what drives the most important treatment decisions, since that is the measure most tied to long-term outcomes.

Fatty Liver in Children and Adolescents

Fatty liver disease is no longer an adult problem. As childhood obesity rates have risen, so has pediatric MASLD. The treatment approach in children focuses heavily on lifestyle intervention, and when weight loss is achieved, the results in young patients can be excellent.²⁵ Getting this under control early may prevent the need for liver-related interventions later in life.

Drug options for children are extremely limited. The TONIC trial, one of the largest pediatric studies, tested vitamin E and metformin against placebo in children with NASH. Vitamin E significantly outperformed placebo, with 58 percent of vitamin E-treated children achieving NASH resolution compared to 28 percent on placebo. Metformin showed some improvement in cell ballooning but did not achieve meaningful results on other measures.²⁶ A Mediterranean-style diet has also shown moderate improvements in liver enzymes in pediatric meta-analyses, though changes in weight and lipid profiles were less convincing.²⁷ The bottom line for young patients: family-wide dietary changes and increased physical activity are the foundation, with vitamin E as the best-studied pharmacological option if lifestyle alone is not enough.

Supplements and the Gut-Liver Connection

Milk thistle (silymarin) is the supplement most commonly associated with liver health, and some data supports modest benefits. A small study of patients awaiting bariatric surgery found that eight weeks of silymarin supplementation improved liver enzyme ratios and ultrasound grading of fatty liver, though it did not change fibrosis scores or FIB-4 markers.²⁸ This is a pattern you see repeatedly with supplements for fatty liver: they may modestly improve surface-level markers without clearly changing the deeper structural damage that matters most.

Research into the gut-liver axis, the relationship between intestinal bacteria, intestinal barrier function, and liver inflammation, is an active area. The liver receives blood directly from the gut via the portal vein, so when the intestinal barrier is compromised (sometimes called “leaky gut”), bacterial products can reach the liver and drive inflammation. Some randomized trials have explored probiotics and agents that restore intestinal barrier function, but results have been inconsistent so far.²⁹ This is a space to watch, but not one with actionable treatments yet.

Emerging Drug Targets on the Horizon

Beyond resmetirom and the GLP-1 drugs, the next wave of treatments likely includes FGF21 analogues. FGF21 is a hormone-like protein involved in fat metabolism, insulin sensitivity, and energy balance. Multiple synthetic versions, including efruxifermin, pegozafermin, and efimosfermin, have shown meaningful histological improvements in patients with fibrotic MASH in phase 2 clinical trials.³⁰ What makes them interesting is the breadth of their effects: they don’t just target the liver in isolation but appear to improve metabolism more broadly, which could make them useful across the spectrum of metabolic diseases.³¹ Phase 3 trial data will determine whether any of these reach the market in the next few years.

Why Genetics May Change How You Respond to Treatment

Not everyone responds to fatty liver treatments the same way, and genetics is one reason. The PNPLA3 gene variant (known as I148M) is the best-studied genetic risk factor for fatty liver, and it appears to affect treatment response. In one trial testing omega-3 fatty acid supplementation, people homozygous for the PNPLA3 risk variant had significantly higher liver fat at the end of the study compared to non-carriers, even after adjusting for other factors, suggesting the genetic variant made them more resistant to the treatment’s effects on liver fat.³² Similarly, carriers of PNPLA3 and TM6SF2 risk variants showed significantly greater increases in liver fat and liver enzymes when exposed to a glucagon receptor antagonist drug, compared to non-carriers.³³

Genetic testing for fatty liver is not standard practice yet, but it may become relevant as more targeted therapies emerge. Someone who carries the PNPLA3 risk variant, for example, may need more aggressive treatment earlier, or may respond differently to specific drugs. The field is slowly moving toward stratifying patients not just by how much fibrosis they have, but by their underlying genetic susceptibility. For now, awareness that genetics plays a role helps explain why two people with similar diets and body weights can have very different degrees of liver disease, and why treatment that works brilliantly for one person may underperform for another.